Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine
A Longitudinal Phase 2 Study for the Continued Evaluation of the Safety and Immunogenicity of a Live Francisella Tularensis Vaccine, NDBR 101, Lot 4
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Maryland
-
Fort Deterick, Maryland, United States, 21702
- U.S. Army Medical Research Institute of Infectious Diseases
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:>
- At least 18 years old, or if on active military duty, 17 years old >
- Females of childbearing potential must agree to have a urine pregnancy test immediately before vaccination (Exception: documented hysterectomy or > 3 years of menopause). The results must be negative. Volunteers must agree not to become pregnant for 3 months after receipt of the vaccine.>
- Subject must be actively enrolled in the SIP >
- Subjects must be considered at risk for exposure to F. tularensis.>
- Subjects must have an up-to-date (within 1 year) medical history, physical examination, and laboratory tests on their charts and be medically cleared for participation by an investigator. Examinations or tests may be repeated within 1 year at the discretion of the enrolling physician.>
- Volunteer must be willing to return for all follow-up visits on days 1, 2, 7, once between days 12-16, and once between days 28-35, days 56-84 (if needed), all visits for serology, as well as an annual visit while enrolled in protocol.>
- Volunteer must agree to report any Adverse Event which may or may not be associated with administration of the test article for at least 28 days after vaccination. All Serious and Unexpected Adverse Events will be reported for the duration of the volunteer's participation in the study. >
Exclusion Criteria:>
- Clinically significant abnormal lab results including evidence of Hepatitis C*, Hepatitis B* carrier state, or elevated liver function tests (2X normal values or at discretion of PI).>
- Personal history of an immunodeficiency or current treatment with an oral or intravenous immunosuppressive medication.>
- Confirmed HIV* infection.>
- Any other medical condition at the discretion of the PI.>
- Antibiotic therapy for 7 days before vaccination.>
- Females must not be pregnant or lactating (females must agree to not become pregnant for 3 months after vaccination).>
- Any known allergies to excipients of the vaccine>
- Administration of another live vaccine within 4 weeks or an inactivated vaccine (generally) within 7 days of tularemia vaccination.>
- Any unresolved adverse event resulting from a previous immunization. >
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: F tularensis Vaccine (0.0025 mL)
Subjects receive a small amount of F tularensis vaccine (0.0025mL) placed on a cleansed site on the skin on the volar surface of the forearm.
A bifurcated needle was used to make 15 superficial punctures at the vaccination site to permit percutaneous penetration of the vaccine.
|
Subjects will receive one drop of reconstituted F tularensis vaccine (approximately 0.0025 ml), applied with a bifurcated needle to the volar surface of the forearm, and the skin will be pricked 15 times over the prepared area.
A booster dose will be given at the same dose volume and route of administration if the titer (days 56-84) is inadequate (< 1:20).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety: Adverse Event Category Rates for All Vaccinations
Time Frame: AEs/SAEs recorded through duration of study; immunogenicity via MA on days 0, 28-35, 56-84, and at 1 year
|
AE analysis was conducted for all intent-to-treat subjects regardless of compliance with titer schedule.
|
AEs/SAEs recorded through duration of study; immunogenicity via MA on days 0, 28-35, 56-84, and at 1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Immunogenicity: Protocol Compliant Post-primary Titer Rates
Time Frame: 12 months
|
Percentage of subjects with less than or greater than titers (> or < 1:20) for compliant post-primary titers.
|
12 months
|
|
Immunogenicity: Protocol-compliant Post-boost 1 Titer Rates
Time Frame: 12 months
|
Percentage of subjects with less than or greater than titers (> or < 1:20) who received post-boost 1
|
12 months
|
|
Immunogenicity: Protocol-compliant Post-boost 2 Titer
Time Frame: 12 months
|
Percentage of subjects with less than or greater than titers who received post-boost 2. Responder = > 1:20 Non-responder = < 1:20 |
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- A-12775
- FY03-24 (Other Identifier: SIP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.